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Abstract
Aims/hypothesis The aim of this cohort study was to
investigate the risk of malignant neoplasms and mortality
in patients with diabetes treated either with human insulin
or with one of three insulin analogues.
Methods Data were provided by the largest German
statutory health insurance fund (time-frame: January 1998
to June 2005 inclusive), on patients without known
malignant disease who had received first-time therapy for
diabetes mellitus exclusively with human insulin, aspart,
lispro or glargine. The primary outcome was the diagnosis
of a malignant neoplasm. Data were analysed by multiple
Cox regression models adjusting for potential confounders.
Results A total of 127,031 patients were included, with a
mean follow-up time of 1.63 (median 1.41, maximum 4.41)
years. A positive association between cancer incidence and
insulin dose was found for all insulin types. Because patients
receiving combined therapy with insulin analogues and
human insulin were excluded, the mean daily dose was much
lower forglarginethanfor human insulin,and a slightlylower
cancer incidence in the glargine group was found. After
adjusting for dose, a dose-dependent increase in cancer risk
was found for treatment with glargine compared with human
insulin (p<0.0001): the adjusted HR was 1.09 (95% CI 1.00
to 1.19) for a daily dose of 10 IU, 1.19 (95% CI 1.10 to 1.30)
for a daily dose of 30 IU, and 1.31 (95% CI 1.20 to 1.42) for
a daily dose of 50 IU. No increased risk was found for aspart
(p=0.30) or lispro (p=0.96) compared with human insulin.
Conclusions/interpretation Considering the overall rela-
tionship between insulin dose and cancer, and the lower
dose with glargine, the cancer incidence with glargine was
higher than expected compared with human insulin. Our
results based on observational data support safety concerns
surrounding the mitogenic properties of glargine in diabetic
patients. Prospective long-term studies are needed to further
evaluate the safety of insulin analogues, especially glargine.
Keywords Aspart.Cohortstudy.Diabetes.Glargine.
Humaninsulin.Insulin analogue.Lispro.Mortality.
Neoplasm
Abbreviations
AOK Allgemeine Ortskrankenkasse (local healthcare fund)
ATC Anatomical Therapeutic Chemical
ICD International Classification of Diseases
Introduction
Although insulin has predominantly metabolic effects, it also
has weak direct and indirect mitogenic properties [1, 2]. A
higher risk of several types of malignant neoplasm has been
found in people with diabetes in systematic reviews of
epidemiological studies. In patients with diabetes mellitus,
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Berlin, Germanycompared with individuals without this condition, Larsson et
al. found an RR of 1.30 (95% CI 1.20 to 1.40) for colorectal
cancer, 1.24 (95% CI 1.08 to 1.42) for bladder cancer, and
1.20 (95% CI 1.12 to 1.28) for breast cancer [3–5]. An OR of
1.82 (95% CI 1.66 to 1.89) has been reported for pancreatic
cancer, and an RR of 2.10 (95% CI 1.75 to 2.53) has been
calculated for endometrial cancer [6, 7]. Similar results have
been reported for other cancer entities. An exposure–response
relationship was reported by Yang et al., who found
indications that the duration of insulin treatment was
positively associated with an increase in the incidence of
colorectal cancer among type 2 diabetic patients [8].
Several insulin analogues have been developed in recent
years and these are increasingly being used in the treatment of
diabetes. However, modifying the insulin molecule not only
changes its metabolic effects, but can also alter its mitogenic
potency. Although it has been shown that the differences in
growth-promoting and mitogenic potencies between human
insulinandinsulinanalogues,aswellasbetweentheanalogues
themselves, are related to different affinities to the IGF-I
receptor, the exact mechanisms are not fully understood, and
the clinical importance of this finding remains unclear [9, 10].
Comparison of the mitogenic potency of insulin analogues
relative to human insulin in cell experiments showed that
B10Asp was tenfold and glargine (A21Gly,B31Arg,B32Arg
human insulin) was eightfold more potent, whereas lispro
(B28Lys,B29Pro human insulin) and aspart (B28Asp human
insulin) were slightly less potent [10].
The proliferative effects of insulin analogues on mam-
mary epithelial cells relative to human insulin have recently
been analysed; at physiologically relevant concentrations, a
significantly higher proliferative effect on MCF-7 breast
cancer cells was found for glargine, but not for aspart or
lispro [11]. In addition, recent experiments with colorectal,
prostate and breast cancer cell lines showed that glargine
and lispro stimulated cancer cell proliferation significantly
more than human insulin did [12].
In vivo carcinogenicity was first demonstrated for the
B10Asp insulin analogue, which, in contrast to human
insulin, induced mammary tumours in rats [13]. Animal
experiments using high-dose glargine have been inconclu-
sive because of the excessive short-term mortality from
repeated severe hypoglycaemia and subsequent neuronal
necrosis or cardiovascular failure [14].
Because of safety concerns, long-term studies to evaluate
the safety of insulin analogues have been demanded [15].
However, to our knowledge, there have not been any
randomised or non-randomised trials conducted in humans
that have been designed and sufficiently powered to detect
differences in carcinogenic safety between insulin ana-
logues and human insulin [16–18].
Our objective was to conduct a cohort study to investigate
the risk of malignant neoplasms in patients with diabetes
treated either with human insulin or an insulin analogue,
taking into consideration important potential confounders and
effect modifiers.
Methods
Data Pseudonymous data on all insurants of Germany’s
largest statutory health insurance fund, the Allgemeine
Ortskrankenkasse (AOK; local healthcare fund), were
provided by Wissenschaftliches Institut der AOK (AOK
Research Institute) for 13 of 16 federal states, representing
17.9 million people. The following data were available for
the total period between 1 January 1998 and 30 June 2005:
(1) basic data (patient ID, age, sex); (2) data from primary
care prescriptions for insulin billed to the AOK (including
information on the insulin type and dose); (3) data from
primary care prescriptions for concomitant medications
billed to the AOK (classified with the German version of
the Anatomical Therapeutic Chemical [ATC] Classification
System [19]); (4) data from hospital claims billed to the
AOK (date of admission, date of discharge, diagnoses at
admission and discharge according to the International
Classification of Diseases, 10th revision, German Modifica-
tion (ICD 10; available at www.dimdi.de/dynamic/de/klassi/
downloadcenter/icd-10-gm/vorgaenger/version2005/
systematik/x1gbp2005.zip, accessed 29 May 2009); (5)
data on the survival status of AOK members. For one of the
federal states (Bavaria), data were not available for the
whole time period.
Study population and definition of variables The study
population comprised adult (≥18 years) patients without
known malignant disease who had received first-time insulin
therapy for diabetes mellitus exclusively with human insulin
or with only one type of insulin analogue. We restricted the
type of insulin analogue to the short-acting analogues lispro
and aspart and the long-acting analogue glargine, as other
analogues had not been on the German market long enough
for evaluation. The diagnosis ‘diabetes mellitus’ was derived
fromprescriptiondata,ashumaninsulinandinsulinanalogues
are only prescribed to patients with diabetes. No definite
distinction between diabetes types 1 and 2 could be made on
the basis of these data and noinformation oninsulin treatment
modalities (e.g. number of insulin injections, insulin pump)
was available; however, it is very likely that patients treated
with insulin and oral glucose-lowering agents had type 2
diabetes mellitus. We classified participants as insulin-naive if
they had not received any prescription for human insulin or
insulin analogues within 1 year before inclusion in the study.
We considered participants to be without known malignant
disease if they had not received a corresponding diagnosis
within 3 years prior to inclusion in the study. To ensure that
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ipants with the slightest suspicion of a malignant disease (e.g.
patients with the ICD-10 diagnosis Z03.1—observation for
suspected malignant neoplasm). Data on the following
potential confounders were available at baseline: age, sex,
yearofstart oftreatment,AOK branch(name offederal state),
number of hospital stays, duration of hospitalisation and
concomitant medications. Data on hospitalisation and con-
comitant medication refer to the time period 3 years prior to
the study entry date. Individual doses of human insulin and
insulin analogues were available as the cumulative dose over
time. We divided the cumulative dose for each participant by
the time at risk, i.e. the days until an event or until censoring,
to obtain a mean daily dose for each participant. We excluded
participants with implausibly high daily doses (>1000 IU), as
well as participants with an event date that was equal to the
study inclusion date.
Definition of cohorts We defined four study groups accord-
ingtothetreatment received: humaninsulin,aspart,lisproand
glargine. Eligible participants were those exposed to only one
of these agents during follow-up. Patients who received any
concomitant insulin prescriptions were excluded, as were
patients who received porcine or bovine insulin.
Outcomes The predefined primary outcome was the diag-
nosis of a malignant neoplasm, which was defined accord-
ing to ICD-10 (diagnoses C00-C97 and D00-D09) or the
corresponding diagnoses in ICD-9. The secondary outcome
was all-cause mortality.
Follow-up Because of the required preceding period of
3 years without known malignant disease, the earliest
possible study inclusion date (start of treatment with human
insulin or an insulin analogue) was 1 January 2001. Follow-
up ended when an event occurred or on 30 June 2005
(study end). Follow-up also ended if the patient cancelled
his or her membership of the AOK. Continuous follow-up
was ensured, as we only analysed data for patients with at
least one insulin prescription every 6 months until an event
occurred or until the end of the observation period.
Statistical analysis We used the χ² test to compare
categorical variables between the treatment groups at
baseline. We applied analysis of variance (ANOVA, F test)
for comparison of continuous covariates between the
treatment groups at baseline. We applied survival time
methods for time-to-event data [20]. Patients who did not
experience an event during the study period were censored
at study end. For the analysis of the time until the
occurrence of a malignant neoplasm, patients who died
without a prior diagnosis of malignant neoplasm were
censored at the last observation date before death. We used
HRs as effect measures, calculated by means of Cox
proportional hazards regression models [21]. We applied
multiple Cox regression models to adjust for potential
confounders. Starting with a Cox model including all given
potential confounders as main effects, we performed a
backward selection procedure with a significance level of
α=0.01 to identify covariates significantly associated with
the time to event. The federal states and the year of
treatment were selected ‘en bloc’, i.e. either all or none of
the categories of the covariate were included in the model.
The scale of the continuous covariates was assessed using a
graphical procedure proposed by Hosmer and Lemeshow
[20]. In this procedure, a Cox model is fitted after
categorising the continuous covariates into groups formed
by the quartiles of the covariates. The estimated coefficients
of the groups are then plotted against the midpoints of the
groups. If the effect of the covariates is linear in the
logarithmically transformed hazard, the polygon connecting
these points forms an approximately straight line. We
checked the proportional hazard assumption graphically
by plotting log(-log survival time) versus log survival time
and by a formal test based on Schoenfeld residuals [22]. If
the proportional hazard assumption was violated, a strati-
fied Cox model was fitted. We assessed possible inter-
actions between the most relevant covariates—insulin
group, sex, age, and dose—by performing a backward
selection procedure based on a Cox model including all
significant main effects and interaction terms at level α=
0.01. As this study was intended to generate hypotheses, we
made no adjustments for multiple testing [23]. All analyses
were performed with the SAS statistical package, Version
9.1 (SAS Institute, Cary, NC, USA).
Results
Out of nearly 18 million insurants and 322,732 insulin-
treated diabetic patients, we included a total of 127,031
eligible patients in the analysis. Figure 1 shows a flow chart
of the data and Table 1 shows the baseline characteristics of
the patients analysed. The baseline characteristics of
patients within different dose ranges for human insulin
and glargine are presented in Electronic supplementary
material (ESM) Table 1.
The mean follow-up time was 1.63 years (median 1.41,
maximum 4.41) for malignant neoplasms and 1.67 years
(median 1.50, maximum 4.41) for mortality after starting
human insulin or insulin analogue therapy. The time under
observation for malignant neoplasms was 1.70 years for
human insulin, 1.44 years for aspart, 2.10 years for lispro
and 1.31 years for glargine; the difference between the
groups was significant (p<0.0001 by ANOVA). The
corresponding values for mortality were only slightly
1734 Diabetologia (2009) 52:1732–1744higher. The mean duration of follow-up was shorter for
those patients prescribed glargine or aspart owing to the
later introduction of these analogues to the German market
(1999 and 2000, respectively).
Among the 127,031 insulin-treated diabetic patients
included in the study, malignant neoplasms were observed
in 5,009 patients and 18,253 patients died. The crude
incidence rate (per 100 patient-years) for malignant neo-
plasms was 2.50 in patients treated with human insulin,
2.16 in those treated with aspart, 2.13 in those treated with
lispro and 2.14 in those treated with glargine. The crude
incidence rate for the secondary endpoint, mortality, was
9.24, 5.75, 6.91 and 6.30, respectively.
The mean (SD) insulin dose until the occurrence of a
malignant neoplasm was 43.8 (37.4) IU for human insulin,
38.9 (33.7) IU for aspart, 36.2 (32.7) IU for lispro and 25.9
(22.5) IU for glargine (p<0.0001 by ANOVA). The median
(and lower quartile, upper quartile and 95% quantile) was
37.0 (21.1, 56.2, 100) IU for human insulin, 33.0 (20.0,
49.3, 98.4) IU for aspart, 31.0 (15.2, 49.2, 91.6) IU for
lispro and 21.8 (14.8, 30.0, 59.3) IU for glargine. The
corresponding values for mortality differed only marginally.
ESM Tables 2 and 3 summarise the final multiple Cox
models for the primary outcome, a diagnosis of a malignant
neoplasm, and the secondary outcome, all-cause mortality,
respectively, including significant interactions and interac-
tions between insulin group and dose.
Significance levels other than α=0.01 (α=0.05 or α=
0.15) in the backward selection procedure essentially led to
the same results for the parameter estimates of the treatment
groups. The assessment of the scale of the continuous
covariates suggested a linear association for all continuous
Aspart
n=4,103
Lispro
n=3,269
Glargine 
n=23,855 
Patients excluded: 
Patients with a diagnosis of  
malignant neoplasm within 3 years  
prior to first prescription of human  
insulin or an insulin analogue  n=14,736  n=291  n=437  n=1,466 
Patients with a suspected  
malignant neoplasm within 3 years  
prior to first prescription of human  
 insulin or an insulin analogue  n=16,430  n=329  n=499  n=1,695 
Patients with insulin treatment  
within 1 year prior to first  
prescription of human insulin or  
an insulin analogue  n=99,616  n=163  n=3,033  n=351 
Patients with an event date  
equal to the study inclusion date  n=5,846  n=223  n=188  n=1,635 
Patients with implausible mean 
daily insulin doses (>1,000 IU)  n=186  n=2  n=4  n=8 
(Note: patients could fulfil more than one exclusion criterion) 
Database: members of the German local healthcare fund (AOK) 
Pseudonymous data of patients older than 18 years with a diagnosis of 
diabetes mellitus type 1 or 2 (time frame: 1 January 1998 to 30 June 2005) n=322,732
Patients excluded: 
Patients receiving human insulin together 
with an insulin analogue, or patients receiving 
more than one insulin analogue  
(lispro, aspart or glargine)  n=71,784
Patients receiving porcine or bovine insulin  n=5,788
(Note: patients could fulfil more than one exclusion criterion)
Aspart
n=4,777
Lispro
n=6,732
Glargine
n=27,347
Human insulin
n=95,804
Human insulin
n=209,408
Fig. 1 Flow diagram of the data
analysed
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Variable Human insulin Aspart Lispro Glargine p value
a
No. of patients 95,804 4,103 3,269 23,855
Age [years], mean (SD) 69.6 (13.1) 66.2 (13.2) 66.8 (13.4) 69.5 (11.6) <0.0001
Sex (male/female) 41.2/58.8 47.5/52.5 47.6/52.4 44.2/55.8 <0.0001
Hospital stays during the 3 years before baseline <0.0001
0 35.3 44.3 35.7 48.2
1–2 41.3 37.7 42.4 35.5
>2 23.4 18.0 21.9 16.2
Duration of hospital stays during the
3 years before baseline [days], mean (SD)
22.6 (35.6) 15.0 (26.0) 20.9 (34.2) 13.8 (25.4) <0.0001
Federal states <0.0001
Bavaria 8.8 12.5 8.8 19.9
Berlin 8.2 7.6 5.6 4.9
Brandenburg 10.2 7.0 12.1 7.1
Bremen 1.6 1.3 1.6 1.1
Hamburg 2.6 2.1 1.6 1.6
Hesse 13.4 14.2 17.5 12.2
Lower Saxony 8.2 8.6 9.2 7.7
Mecklenburg–Western Pomerania 7.3 6.9 4.1 7.7
Rhineland 8.5 10.3 7.5 11.0
Saarland 2.8 2.4 2.7 3.8
Saxony–Anhalt 7.1 11.4 7.6 9.1
Schleswig–Holstein 6.1 3.1 5.3 3.9
Westphalia–Lippe 15.3 12.5 16.5 10.2
Start of therapy with human insulin or insulin analogues <0.0001
2001 16.4 4.2 30.2 5.3
2002 18.1 13.8 18.6 10.4
2003 26.2 33.2 22.6 28.0
2004 27.5 34.9 19.9 38.1
2005 (January to June) 11.9 14.0 8.7 18.2
Concomitant medication
Oral glucose-lowering agents 77.2 80.1 66.0 92.1 <0.0001
Biguanides (metformin) 48.8 55.4 40.8 63.9
Sulfonylureas 66.7 64.5 54.2 79.8
α-Glucosidase inhibitors 13.1 13.6 11.8 17.4
Glitazones 4.8 6.9 4.3 8.5
Others 0.8 1.7 1.4 1.0
ACE inhibitors 64.9 64.7 61.5 66.4 <0.0001
Anaesthetics 1.1 0.8 0.7 1.2 0.03
Analgesics 45.8 46.8 39.3 44.9 <0.0001
Antiallergics 8.2 8.8 7.7 8.0 0.21
Antiarrhythmic agents 2.1 1.8 1.7 1.7 0.004
Antibiotics 51.1 55.5 45.3 53.2 <0.0001
Antidotes 0.1 0.1 0.2 0.1 0.08
Antiepileptics 5.4 5.2 5.0 5.1 0.42
Antihypertensives 10.0 10.9 9.3 10.0 0.16
Antirheumatic agents 58.8 65.6 53.9 64.1 <0.0001
Antitussives 35.3 38.9 32.8 38.3 <0.0001
Beta blockers 44.2 44.6 41.7 44.5 0.03
Bronchodilators 18.1 19.7 17.7 17.0 <0.0001
1736 Diabetologia (2009) 52:1732–1744covariates. Thus, all continuous covariates were included as
a linear term in the final model. Graphical checks indicated
a possible deviation from the proportional hazard assump-
tion for the factor ‘dose’ for both outcomes. Thus, a
stratified Cox model was fitted, using quantiles of the dose
as the strata. This model essentially yielded the same HRs
for the insulin groups as the unstratified Cox model.
Tables 2 and 3 show the results of intermediate models
with different degrees of complexity to enable a better
assessment of the influence of the different covariates on
the primary and secondary outcomes, respectively. The
results of a model including age, sex and dose in addition to
treatment group as the only covariates are consistent with
the main results of the final Cox model. In a model
adjusting for age and sex, dose had a significant overall
effect on the incidence of malignant neoplasms (p<0.0001).
The significant dose effect remained when each insulin type
was analysed separately.
Because the final multiple Cox models contain interaction
terms between the insulin analogues and dose, the adjusted
HRs for insulin analogues compared with human insulin
change when the dose is varied. Therefore, in Tables 2 and 3
the adjusted HRs from the final model are given for different
dose levels. Figure 2 further illustrates the adjusted HRs for
the insulin analogues compared with human insulin regard-
ing malignant neoplasms and mortality in relation to the
insulin dose, based on the final multiple Cox model.
To check the robustness of the results, we conducted
several sensitivity analyses. To assess detection bias, we
analysed the potential influence of particular tumour
entities to identify potential bias caused by malignant
neoplasms that were possibly already prevalent but undi-
agnosed at study entry; skin cancer (C44), precancerous
lesions and in situ carcinoma (D00–D09) were not treated
as malignant neoplasms in further analyses. Furthermore,
we considered a subclassification of treatment with oral
glucose-lowering agents. Table 4 summarises the results of
the sensitivity analyses. To further illustrate and analyse the
dose-dependent risk increase with glargine, we performed
additional analyses. Detailed analyses of subgroups of
patients treated with different doses of glargine or human
insulin are given in Table 5. Table 6 shows the change in
incidence rates of malignant neoplasms and mortality per
dose increase of 1 SD (within each treatment group).
Table 1 (continued)
Variable Human insulin Aspart Lispro Glargine p value
a
Calcium antagonists 34.5 32.4 31.2 33.7 <0.0001
Corticosteroids 14.2 15.7 12.9 12.1 <0.0001
Dermatologicals 44.6 46.8 38.2 45.9 <0.0001
Diuretics 51.2 46.9 44.1 45.9 <0.0001
Antigout agents 17.4 18.6 17.2 17.4 0.19
Gynaecologicals 6.6 6.7 5.1 5.6 <0.0001
Haematologicals 52.2 48.2 47.4 48.0 <0.0001
Immune-modifying agents 1.9 2.1 1.9 1.4 <0.0001
Cardiac agents 28.7 22.2 22.8 25.3 <0.0001
Agents for coronary heart disease 28.8 25.2 25.6 26.7 <0.0001
Agents for liver disease 2.5 2.8 2.4 2.3 0.21
Lipid-lowering agents 28.5 32.3 29.8 31.5 <0.0001
Gastrointestinal agents 51.1 51.0 47.5 48.1 <0.0001
Agents for diseases of the parathyroid gland 2.2 2.1 1.7 2.0 0.16
Parasympathomimetics 0.3 0.5 0.2 0.3 0.21
Anti-Parkinson agents 4.4 3.6 3.0 3.9 <0.0001
Psychopharmacologicals 36.5 33.1 31.8 34.0 <0.0001
Agents for diseases of the thyroid gland 15.1 14.6 14.0 15.6 0.04
Sex hormones 9.7 10.7 9.2 10.1 0.06
Urologicals 13.5 13.8 12.7 14.5 0.0001
Vitamins 12.5 12.8 12.7 12.6 0.94
Cytostatic agents (prescribed for non-malignant diseases) 1.6 1.5 1.2 1.6 0.26
Numbers are percentages (if not specified otherwise)
aF test for continuous variables, χ
2 test for proportions
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Theresultsofourstudyindicatethat,inpatientswithdiabetes,
the insulin dose is positively associated with the risk of
malignant neoplasms; this applies both to human insulin and
toinsulinanalogues.Comparedwithhumaninsulin,thisdose-
dependent risk increase was higher for glargine (p<0.0001)
but not for lispro (p=0.96) or aspart (p=0.30).
In this pragmatic cohort study there were notable
differences between the baseline characteristics of the
treatment groups. This underlines the importance of
accounting for confounding factors by applying a careful
model-building process including relevant covariates and
interaction terms.
At baseline, the patients in the glargine group seemed to
be healthier than those in the human insulin group (fewer
and shorter hospital stays), and the mean daily dose was
significantly lower in the glargine group, leading to a
significantly lower risk in the unadjusted analysis as well as
in the analysis adjusted for age and sex, in which the
modifying effects of dose were not taken into account.
After also adjusting for dose, a significantly higher risk was
observed for glargine relative to human insulin (Table 2).
This means that glargine is associated with a higher risk of
malignant neoplasms when the risk is adjusted for patients’
characteristics and the insulin dosage. Our findings are in
line with the previously demonstrated in vitro mitogenic
potency of glargine [10–12].
Our study has both strengths and limitations. The major
strength of our study is the evaluation of a comprehensive
data set from the largest German statutory health insurance
fund, which is most likely to be representative of insulin-
treated diabetic patients in Germany. Our access to these
data enabled the analysis of almost 130,000 diabetic
patients treated with insulin who were observed over a
mean period of 1.63 years for malignant neoplasms under
real-life conditions. For four of the 16 federal states in
Germany, data were either missing or only partly available.
This was due to technical reasons and, in our view, did not
influence the representative nature of the database.
One major limitation of the study is the fact that patients
werenotrandomisedtotreatmentgroups.Althoughtheresults
Table 2 Intermediate and final models with HRs (95% CIs) for insulin analogues (reference group: human insulin) for malignant neoplasms
Covariates Aspart Lispro Glargine
None 0.86 (0.73–1.03) 0.85 (0.72–1.01) 0.85 (0.79–0.93)
Age, sex 0.95 (0.79–1.13) 0.90 (0.76–1.06) 0.86 (0.79–0.94)
Age, sex, dose 1.01 (0.85–1.21) 0.99 (0.84–1.16) 1.14 (1.05–1.24)
Age, sex, dose, oral glucose-lowering agents 1.02 (0.86–1.22) 0.98 (0.83–1.15) 1.16 (1.07–1.27)
Age, sex, dose, oral glucose-lowering agents,
hospitalisation
a
1.03 (0.86–1.23) 0.98 (0.83–1.16) 1.18 (1.08–1.28)
Age, sex, dose, oral glucose-lowering agents,
concomitant medication
1.02 (0.86–1.22) 0.99 (0.84–1.17) 1.17 (1.07–1.27)
Age, sex, dose, oral glucose-lowering agents,
concomitant medication, federal state, year
1.02 (0.85–1.22) 0.99 (0.84–1.17) 1.18 (1.08–1.28)
Age, sex, dose, oral glucose-lowering agents,
concomitant medication, hospitalisation
a
1.03 (0.86–1.23) 0.99 (0.84–1.17) 1.18 (1.08–1.28)
Age, sex, dose, oral glucose-lowering agents,
concomitant medication, federal state,
year, hospitalisation
a
1.03 (0.86–1.22) 0.99 (0.84–1.17) 1.19 (1.09–1.29)
Selected covariates (main effects)
b 1.02 (0.85–1.21) 0.99 (0.84–1.17) 1.18 (1.08–1.28)
Age, sex, dose, interaction term dose × insulin
c p=0.82
d p=0.94
d p<0.0001
d
10 IU 1.04 (0.86–1.26) 0.97 (0.80–1.18) 1.06 (0.97–1.15)
30 IU 1.03 (0.86–1.24) 0.98 (0.83–1.16) 1.15 (1.06–1.25)
50 IU 1.02 (0.86–1.22) 0.99 (0.84–1.17) 1.25 (1.15–1.36)
Final model: selected covariates (main effects and interactions)
b,c p=0.30
d p=0.96
d p<0.0001
d
10 IU 1.00 (0.82–1.21) 0.99 (0.82–1.19) 1.09 (1.00–1.19)
30 IU 1.02 (0.85–1.22) 0.98 (0.83–1.16) 1.19 (1.10–1.30)
50 IU 1.04 (0.87–1.24) 0.98 (0.83–1.16) 1.31 (1.20–1.42)
a‘Hospitalisation’ comprises number and duration of hospital stays
bSee ESM Table 2.
cBecause of the dose-dependent effect size, the adjusted HR is shown for three dose levels
dp value refers to a simultaneous test of main effects and all corresponding interaction effects
1738 Diabetologia (2009) 52:1732–1744were adjusted for all known and available confounders,
potentially relevant factors such as insulin resistance, body
mass index, smoking, social status and duration of diabetes
werenotavailableandthereforecouldnotbeconsideredinthe
analyses. However, to explain the observed dose-dependent
riskincreaseintheglarginegroup,thesepotentialconfounders
wouldhavetobeassociatedwithbothahighercancerriskand
a higher glargine dosage. For example, we have no evidence
that the glargine group included more smokers or people from
a lower socioeconomic class; in fact, at baseline, the glargine
group generally seemedtobehealthier thanthe human insulin
group, and these findings were consistent when comparing
subgroups of patients within the same dose range.
Although we tried to consider bias as much as the
available data allowed, we cannot entirely exclude the
possibility that some known or unknown factors could have
influenced both the dose of human insulin and insulin
analogues and the risk of cancer, especially given that the
groups being compared were clinically dissimilar. Ulti-
mately, only a randomised controlled trial could dispel
these concerns. Such an analysis would also require the
follow-up of large patient groups. In our study, the patient
numbers were highest for human insulin and glargine.
Hence, the conclusions are less robust for aspart and lispro.
Detection bias may have occurred because of the more
frequent and longer hospitalisation periods of patients in the
human insulin group compared with those in the glargine
group. This could have resulted in relatively higher
detection rates of neoplasms, particularly skin cancer
(C44), as well as of precancerous lesions and in situ
carcinoma (D00–D09). We took great care to avoid bias
through prevalent but undiagnosed neoplasms when de-
signing this study; hence, we excluded patients with the
slightest suspicion of a malignant disease. We performed
sensitivity analyses including and excluding these particular
entities, and the main results remained unchanged. Further-
more, a higher detection rate of malignant neoplasms in the
human insulin group would lead to an underestimation of
Table 3 Intermediate and final models with HRs (95% CIs) for insulin analogues (reference group: human insulin) for all-cause mortality
Covariates Aspart Lispro Glargine
None 0.63 (0.56–0.70) 0.75 (0.68–0.82) 0.68 (0.65–0.72)
Age, sex 0.82 (0.74–0.91) 0.89 (0.81–0.98) 0.73 (070–0.77)
Age, sex, dose 0.84 (0.76–0.93) 0.91 (0.84–1.00) 0.81 (0.77–0.85)
Age, sex, dose, oral glucose-lowering agents 0.86 (0.77–0.95) 0.90 (0.83–0.99) 0.85 (0.81–0.89)
Age, sex, dose, oral glucose-lowering agents,
hospitalisation
a
0.89 (0.80–0.99) 0.93 (0.85–1.02) 0.90 (0.86–0.95)
Age, sex, dose, oral glucose-lowering agents,
concomitant medication
0.86 (0.77–0.95) 0.96 (0.88–1.05) 0.90 (0.86–0.95)
Age, sex, dose, oral glucose-lowering agents,
concomitant medication, federal state, year
0.89 (0.80–0.99) 0.95 (0.86–1.04) 0.93 (0.89–0.98)
Age, sex, dose, oral glucose-lowering agents,
concomitant medication, hospitalisation
a
0.89 (0.80–0.99) 0.98 (0.89–1.07) 0.94 (0.90–0.99)
Age, sex, dose, oral glucose-lowering agents,
concomitant medication, hospitalisation
a,
federal state, year
0.91 (0.82–1.02) 0.97 (0.89–1.06) 0.96 (0.92–1.01)
Selected covariates (main effects)
b 0.92 (0.82–1.02) 0.97 (0.88–1.06) 0.96 (0.92–1.01)
Age, sex, dose, interaction dose × insulin
c p=0.005
e p=0.14
e p<0.0001
e
10 IU 0.87 (0.74–1.02) 0.92 (0.81–1.05) 0.71 (0.66–0.75)
30 IU 0.84 (0.76–0.94) 0.91 (0.83–1.00) 0.90 (0.86–0.93)
50 IU 0.82 (0.72–0.94) 0.91 (0.82–1.01) 1.14 (1.05–1.23)
Final model: selected covariates
(main effects and interactions)
b,c,d
p=0.14
e p=0.47
e p<0.0001
e
10 IU 0.91 (0.77–1.06) 0.96 (0.84–1.09) 0.76 (0.70–0.83)
30 IU 0.90 (0.78–1.04) 0.95 (0.86–1.04) 0.96 (0.90–1.01)
50 IU 0.89 (0.78–1.02) 0.94 (0.86–1.04) 1.20 (1.11–1.30)
a‘Hospitalisation’ comprises number and duration of hospital stays
bSee ESM Table 3
cBecause of the dose-dependent effect size, the adjusted HR is shown for three dose levels
dBecause of the interaction of glargine with age, the adjusted HR refers to a fixed age of 70 years
ep value refers to a simultaneous test of main effects and all corresponding interaction effects
Diabetologia (2009) 52:1732–1744 1739the true effect, and the real difference between the incidence
rates of the insulin and the glargine groups could be even
greater than the one observed.
Anotherdisparityisthatmorepatientsintheglarginegroup
were treated with oral glucose-lowering agents. To take the
effect of these agents into account, we adjusted for the factor
‘concomitant treatment with any oral glucose-lowering agent’
in the final Cox regression model and additionally for the
specific subclasses of oral glucose-lowering agents in sensi-
tivityanalyses. Inparticular, we analysed a potential influence
of metformin therapy, for which potential effects on cancer
incidence have been previously discussed [24]. However, we
found no evidence in our analyses of a substantial influence
of metformin or any other oral glucose-lowering agent on the
risk of morbidity or mortality.
A further potential limitation is prescription bias.
Members of the human insulin group may have been
treated with both short- and long-acting agents, whereas
patients in the glargine group were treated only with
glargine, and presumably had residual insulin secretion or
received prescriptions for oral agents. Prescription bias
could have affected the results if patients at a higher risk of
malignant neoplasms had been prescribed glargine (at a
higher dosage); however, the glargine group generally
seemed to be healthier at baseline than the human insulin
group (in all dose ranges).
Furthermore, we have no evidence that patients who still
have residual insulin secretion are at a higher risk of
malignant neoplasms than those who require treatment with
human insulin with both short- and long-acting agents.
The fact that the members of the glargine group were
treated only with glargine, i.e. did not receive additional
treatment with a short-acting insulin, contributes to the
observed higher average daily insulin dose in the human
insulingroup.Thiswasnotunexpectedandwas accountedfor
by the study design: we conducted an analysis based on real-
life data representing the usual care of patients treated with
glargine or human insulin. In addition, to avoid confounding,
we explicitly aimed to compare exposure to human insulin
and insulin analogues without overlapping or crossover
effects. Therefore, we included patients who had been
exposed to only one of the types of insulin investigated.
Taking these aspects into account, the slightly lower crude
incidence rate of malignant neoplasms associated with
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1740 Diabetologia (2009) 52:1732–1744glargine compared with human insulin seems to be at least
partly a result of the different doses in the treatment groups.
One also has to take into account that glargine is being
actively marketed promoting the added advantage of once-
daily application in patients who have not reached their
treatment goals with oral glucose-lowering agents alone.
This might have led to an increased use of comparatively
smaller doses of glargine.
We considered these dose differences in subgroup
analyses, and even in these analyses (which only consid-
ered the most relevant covariates) and despite the lower
statistical power, a significantly higher relative risk of
cancer was observed for glargine in the high-dose range.
Considering that the lower number of patients and events
reduced the statistical power, it is not unexpected that we
only found statistically significant differences in the
subgroup that received doses in the highest range.
The observedresults for the secondaryoutcome (mortality)
require closer examination. We observed lower crude mortal-
ity rates in patients treated with glargine doses of <40 IU than
in those treated with human insulin at the same doses (dose
range <20 IU: 5.81 vs 8.83 per 100 patient-years; dose range
20 to 40 IU: 5.58 vs 9.67 per 100 patient-years).
However, we observed higher mortality rates in patients
treated with high doses of glargine (>40 IU) than in patients
treated with equivalent doses of human insulin (14.79 vs
9.17 per 100 patient-years). We carefully adjusted for the
available covariates, took dose effects into account, and
found a treatment–dose interaction caused by the higher
mortality rate in patients treated with high doses. We have
no indication that patients who were at high risk of dying
were more likely to be treated with high doses of glargine
than with human insulin, and the demographic data do not
provide any plausible explanations for this finding. We are
therefore cautious in interpreting these results and we
would need further data to draw any valid conclusions.
Unfortunately, data on cause-specific mortality were not
available and we do not know if causes of death differed
Table 4 Sensitivity analyses: HRs (95% CIs) for insulin analogues (reference group: human insulin) for malignant neoplasms
Description Dose (IU) Aspart Lispro Glargine
Skin cancer (C44) not treated as a neoplasm (n=127,031) p=0.01
a p=0.04
a p<0.0001
a
10 0.91 (0.75–1.11) 0.88 (0.73–1.07) 0.91 (0.83–0.99)
30 0.95 (0.79–1.15) 0.94 (0.79–1.12) 1.03 (0.94–1.12)
50 0.99 (0.83–1.19) 1.00 (0.85–1.19) 1.16 (1.06–1.27)
Precancerous lesions and in situ carcinoma (D00–D09)
not treated as a neoplasm (n=127,031)
p=0.84
a p=0.91
a p<0.0001
a
10 1.04 (0.86–1.25) 0.97 (0.80–1.17) 1.05 (0.96–1.15)
30 1.03 (0.86–1.24) 0.98 (0.82–1.16) 1.14 (1.05–1.24)
50 1.02 (0.86–1.22) 0.99 (0.84–1.17) 1.24 (1.14–1.35)
Oral glucose-lowering agents stratified into subclasses
(biguanides, sulfonylureas, α-glucosidase inhibitors,
glitazones, other oral glucose-lowering agents) (n=127,031)
p=0.84
a p=0.90
a p<0.0001
a
10 1.05 (0.87–1.26) 0.96 (0,79–1.16) 1.09 (1.00–1.19)
30 1.04 (0.87–1.25) 0.97 (0.82–1.15) 1.18 (1.08–1.28)
50 1.03 (0.87–1.23) 0.98 (0.83–1.15) 1.27 (1.17–1.39)
Biguanides (yes/no) as an additional covariate (n=127,031) p=0.83
a p=0.91
a p<0.0001
a
10 1.05 (0.87–1.26) 0.96 (0.79–1.16) 1.07 (0.98–1.17)
30 1.04 (0.87–1.24) 0.97 (0.82–1.15) 1.16 (1.07–1.27)
50 1.03 (0.86–1.23) 0.98 (0.83–1.16) 1.26 (1.16–1.37)
Patients with a follow-up time of at least 1.5 years
b (n=69,766) p=0.06
a p=0.05
a p<0.0001
a
10 0.90 (0.71–1.15) 1.18 (0.91–1.52) 1.06 (0.96–1.18)
30 0.97 (0.78–1.20) 0.98 (0.82–1.18) 1.13 (1.02–1.25)
50 1.03 (0.84–1.28) 0.82 (0.66–1.02) 1.20 (1.08–1.33)
Patients prescribed oral glucose-lowering agents (n=101,389) p=0.60
a p=0.91
a p<0.0001
a
10 1.07 (0.87–1.31) 0.95 (0.75–1.20) 1.04 (0.95–1.15)
30 1.05 (0.86–1.29) 0.96 (0.78–1.18) 1.18 (1.08–1.29)
50 1.04 (0.85–1.26) 0.96 (0.79–1.18) 1.33 (1.21–1.46)
Sensitivity analyses are based on an adjusted model including age, sex, dose and interaction terms of insulin group and dose as covariates.
Because of the dose-dependent effect size, the adjusted HRs are shown for three dose levels
ap values refer to a simultaneous test of main effects and all corresponding interaction effects
bTime between study entry and study end
Diabetologia (2009) 52:1732–1744 1741between the groups. In this regard we would like to point
out that an analysis of patients treated over a longer period
of time would of course have been desirable; however, the
available data were limited because of the framework of
this study. We performed an additional analysis including
only participants with a follow-up time (time between study
entry and end of study) of at least 1.5 years, and found
consistent results regarding the dose-dependent risk of
malignant neoplasms and mortality.
One of the strengths of our study is that the patients were
treated with a single type of insulin, which avoids
confounding between treatments. We think that it would
be difficult to treat diabetic patients over several years with
only one insulin analogue. Moreover, such a study protocol
would in itself create additional confounders.
In our opinion, this issue should be investigated using a
prospective study design, and a reliable assessment of
causes of death should be performed by a clinical review
committee [25]. We plan to conduct additional analyses to
Table 5 Incidence rates and HRs of malignant neoplasms in subgroups of patients within different dose ranges (glargine vs human insulin)
Description Treatment Dose (IU)
<20 20–40 >40
No. of patients (%) G 10,835 (45.4) 9,794 (41.1) 3,226 (13.5)
HI 22,438 (23.4) 29,325 (30.6) 44,041 (46.0)
Patient years of follow-up G 16,657 12,659 1,959
HI 42,815 52,997 66,986
Events G 309 257 103
HI 740 1,251 2,075
Crude incidence rate per 100 patient-years (95% CI) G 1.86 (1.65–2.07) 2.03 (1.79–2.29) 5.26 (4.29–6.38)
HI 1.73 (1.61–1.86) 2.36 (2.23–2.50) 3.10 (2.96–3.23)
HRs (95% CIs)
a
Unadjusted G 1.13 (0.99–1.29) 0.89 (0.78–1.02) 1.42 (1.17–1.74)
H I 111
Adjusted for age G 1.15 (1.00–1.31) 0.97 (0.84–1.11) 1.55 (1.27–1.90)
H I 111
Adjusted for sex G 1.10 (0.96–1.26) 0.88 (0.77–1.01) 1.41 (1.16–1.72)
H I 111
Adjusted for age and sex G 1.12 (0.98–1.28) 0.96 (0.84–1.10) 1.54 (1.26–1.88)
H I 111
Adjusted for oral glucose lowering agents G 1.08 (0.94–1.24) 0.92 (0.80–1.05) 1.44 (1.18–1.76)
H I 111
Adjusted for age, sex, oral glucose-lowering agents G 1.11 (0.96–1.28) 0.99 (0.87–1.14) 1.57 (1.29–1.92)
H I 111
Adjusted for age, sex, hospitalisation
b G 1.14 (0.99–1.30) 0.99 (0.86–1.14) 1.57 (1.28–1.91)
H I 111
Adjusted for age, sex, oral glucose-lowering
agents, hospitalisation
b
G 1.13 (0.98–1.30) 1.02 (0.88–1.17) 1.59 (1.30–1.95)
H I 111
Adjusted for age, sex, oral glucose-lowering
agents, hospitalisation
b, concomitant medication
G 1.13 (0.98–1.30) 1.01 (0.88–1.16) 1.59 (1.30–1.94)
H I 111
aSeparate Cox models for each dose group, adjusted for given covariates
b‘Hospitalisation’ comprises number and duration of hospital stays
G, glargine; HI, human insulin
Table 6 HRs per dose change of 1 SD within each treatment group
based upon separate Cox models for glargine and human insulin,
adjusted for age and sex
Treatment HRs (95% CIs)
Malignant neoplasm Mortality
Glargine 1.78 (1.68–1.89) 1.44 (1.36–1.52)
Human insulin 1.57 (1.54–1.60) 1.20 (1.17–1.22)
1742 Diabetologia (2009) 52:1732–1744further explore the effects of human insulin and insulin
analogues on specific cancer entities.
To our knowledge, the risk of cancer in patients with
diabetes has so far never been compared between patients
treated with human insulin and those treated with insulin
analogues. Despite the relatively fragile nature of the data,
the results of our cohort study support safety concerns
surrounding the mitogenic and potential tumour growth-
promoting properties of glargine. The findings underline
the necessity for a prospective, randomised, controlled,
long-term study that is designed and sufficiently powered to
evaluate insulin analogues with regard to their effects on
morbidity and mortality in patients with diabetes. Taking
into account the fact that a non-randomised study cannot
prove that the association between glargine and cancer is
causal, we still think that our results may have practical
implications. In our view, the decision for or against
treatment with glargine has to be made on an individual
basis after providing comprehensive information to patients
about the limited long-term data available and the uncertain
potential benefits and harms. We think that, especially in
type 2 diabetes mellitus, the potential harm of glargine must
be weighed against rather minor potential therapeutic
advantages [18, 26, 27]. In general, before the widespread
introduction of a new drug that is to be taken for decades,
we think that an evaluation of its patient-relevant beneficial
and harmful effects should be conducted under controlled
conditions for at least several years. Because such studies
are rare and not required for market approval, patients and
physicians will still often have to make treatment decisions
in the face of uncertainty.
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